Prostate Cancer Terminated Phase 2 Trials for Docetaxel (DB01248)

Also known as: Prostatic Cancer / Prostatic neoplasms malignant / Carcinoma Prostate / Cancer Of Prostate / Malignant Neoplasm of Prostate / Prostate Cancers / Prostate carcinoma / Carcinoma of the prostate / Cancer, Prostate / Carcinoma of prostate / Prostatic carcinoma / Carcinoma prostatic / Ca prostate / Prostate cancer NOS

IndicationStatusPhase
DBCOND0062462 (Prostate Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00348816Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate CancerTreatment
NCT02494713Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate CancerTreatment
NCT00480857Salvage Radiation Therapy and Taxotere for PSA Failure After Radical ProstatectomyTreatment
NCT00258765Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.Prevention
NCT00126230Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate CancerTreatment
NCT00176527Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyTreatment
NCT00176631Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyTreatment
NCT00582582Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate CancerTreatment
NCT00577356Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate CancerTreatment
NCT00786682Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate CancerTreatment
NCT00734851Multimodality Phase II Study in Prostate CancerTreatment
NCT00714376Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer PatientsTreatment
NCT00482274Docetaxel in Treating Patients With Relapsed Prostate CancerTreatment